2010
DOI: 10.1007/s00417-010-1470-2
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: BackgroundTo identify predictive factors for improvement of visual acuity and central retinal thickness by intravitreal bevacizumab for the treatment of macular edema (ME) due to branch retinal vein occlusion (BRVO).MethodsTwo hundred and five eyes from 204 patients with ME secondary to BRVO were retrospectively included at six sites. All eyes received intravitreal bevacizumab therapy (1.25 mg/0.05 ml). The mean follow-up was 36.8 ± 12.7 weeks (range, 18 to 54 weeks). Measurement of ETDRS best-corrected visual… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

10
50
0
7

Year Published

2012
2012
2020
2020

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 89 publications
(67 citation statements)
references
References 25 publications
10
50
0
7
Order By: Relevance
“…Other studies have reported similar results (16)(17)(18)(19)(20). Older age was a predictor of worse BCVA in the BRVO, bevacizumab, and ranibizumab groups, which is in agreement with other reports (8,(16)(17)(18)(19)(20). Only in the BRVO group was a lower number of injections during the first 6 months of treatment a predictor of worse BCVA at 6 months.…”
Section: Discussionsupporting
confidence: 90%
“…Other studies have reported similar results (16)(17)(18)(19)(20). Older age was a predictor of worse BCVA in the BRVO, bevacizumab, and ranibizumab groups, which is in agreement with other reports (8,(16)(17)(18)(19)(20). Only in the BRVO group was a lower number of injections during the first 6 months of treatment a predictor of worse BCVA at 6 months.…”
Section: Discussionsupporting
confidence: 90%
“…Similar to our study protocol, fewer injections were performed in 2 different studies that used bevacizumab with a mean number of 2.3 and 2.6 injections in 6 months (18,32). In line with those results, the injection frequency was 2.4 in our study with ranibizumab and we found similar improvement in visual acuity and CRT as in those studies.…”
Section: Discussionsupporting
confidence: 89%
“…In 2010, Ach et al [25] evaluated retinal vein occlusion patients for such predictive factors and found that the CMT and age of patients had prognostic value in cases of central retinal vein occlusion, but that there were no observed predictive factors in cases of BRVO. In contrast, Jaissle et al [26] conducted a study in 2011 that observed that baseline BCVA, patient's age, and duration of BRVO were relevant prognostic factors for visual improvement. The results of this second study correlate with our findings based on Korean patients, which also found significance in baseline BCVA and patient age.…”
Section: Discussionmentioning
confidence: 99%